试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-02
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
编号:NCT02661464登记状态:提前终止企业 / 申办者:Janssen Vaccines & Prevention B.V.
药物 / 成分:Ad26.ZEBOV、MVA-BN-Filo
登记的停止原因(原文):Due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible, the study was terminated early.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
Levetiracetam Treatment of Neonatal Seizures
编号:NCT02550028登记状态:提前终止企业 / 申办者:Children's Hospital of Fudan University
药物 / 成分:Oral levetiracetam、Intravenous phenobarbital
登记的停止原因(原文):The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
Erythropoietin in Premature Infants to Prevent Encephalopathy
编号:NCT02550054登记状态:提前终止企业 / 申办者:Children's Hospital of Fudan University
药物 / 成分:Epo、Normal saline
登记的停止原因(原文):The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
编号:NCT04244552登记状态:提前终止企业 / 申办者:Atreca, Inc.
药物 / 成分:ATRC-101、Pembrolizumab、Pegylated liposomal doxorubicin (PLD)
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)
编号:NCT04738318登记状态:提前终止企业 / 申办者:Vanderbilt University Medical Center
药物 / 成分:Glucocorticoids、Saline
登记的停止原因(原文):Switched to observational study type.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
Comparison Between Subacromial Ultrasound Guided and Systemic Steroid Injection for Frozen Shoulder
编号:NCT04931511登记状态:提前终止企业 / 申办者:Second Affiliated Hospital, Zhejiang University, School of Medicine
药物 / 成分:Compound betamethasone Injection(Gluteal muscle injection)、Compound betamethasone Injection(Subacromial Ultrasound Guided injection)、Physical therapy
登记的停止原因(原文):Since the COVID-19 pendemic, the regular follow-up of participant became very hard. The participant were not willing to go back to the hospital for repeat measurement. So we stop the study and plan to redesign the protocol.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-29
Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
编号:NCT05381363登记状态:提前终止企业 / 申办者:Children's Hospital of Fudan University
药物 / 成分:Inhaled Interferon α2b、Standard of Care
登记的停止原因(原文):The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-28
Metabolic Effects of Hydroxychloroquine
编号:NCT02026232登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Hydroxychloroquine、Hydroxychloroquine Placebo
登记的停止原因(原文):COVID-19 \& loss of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-28
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
编号:NCT04196010登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Cladribine、Cytarabine、Recombinant Granulocyte Colony-Stimulating Factor、Mitoxantrone
登记的停止原因(原文):Terminated due to unfavorable risk-benefit ratio of investigational regimen.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-28
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
编号:NCT04731298登记状态:提前终止企业 / 申办者:Swedish Orphan Biovitrum
药物 / 成分:Emapalumab
登记的停止原因(原文):Sponsor Decision related to Business Priorities, Assessment of Development Options
查看官方原始记录 ↗